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Abstract: The current COVID-19 pandemic has necessitated the need to find healthcare solutions
that boost or support immunity. There is some evidence that high-velocity, low-amplitude (HVLA)
controlled vertebral thrusts have the potential to modulate immune mediators. However, the
mechanisms of the link between HVLA controlled vertebral thrusts and neuroimmune function
and the associated potential clinical implications are less clear. This review aims to elucidate the
underlying mechanisms that can explain the HVLA controlled vertebral thrust–neuroimmune link
and discuss what this link implies for clinical practice and future research needs. A search for relevant
articles published up until April 2021 was undertaken. Twenty-three published papers were found
that explored the impact of HVLA controlled vertebral thrusts on neuroimmune markers, of which
eighteen found a significant effect. These basic science studies show that HVLA controlled vertebral
thrust influence the levels of immune mediators in the body, including neuropeptides, inflammatory
markers, and endocrine markers. This narravtive review discusses the most likely mechanisms for
how HVLA controlled vertebral thrusts could impact these immune markers. The mechanisms are
most likely due to the known changes in proprioceptive processing that occur within the central
nervous system (CNS), in particular within the prefrontal cortex, following HVLA spinal thrusts. The
prefrontal cortex is involved in the regulation of the autonomic nervous system, the hypothalamic–
pituitary–adrenal axis and the immune system. Bi-directional neuro-immune interactions are affected
by emotional or pain-related stress. Stress-induced sympathetic nervous system activity also alters
vertebral motor control. Therefore, there are biologically plausible direct and indirect mechanisms that
link HVLA controlled vertebral thrusts to the immune system, suggesting HVLA controlled vertebral
thrusts have the potential to modulate immune function. However, it is not yet known whether
HVLA controlled vertebral thrusts have a clinically relevant impact on immunity. Further research is
needed to explore the clinical impact of HVLA controlled vertebral thrusts on immune function.
Keywords: high-velocity; low-amplitude thrust; HVLA; chiropractic; spinal manipulation; central
nervous system; prefrontal cortex; immune system; endocrine system
1. Introduction
The COVID-19 pandemic has resulted in significant global morbidity and mortal-
ity [1,2], especially amongst individuals who are immunocompromised, such as older
people and those with underlying medical conditions [2,3]. The current pandemic and
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other infectious diseases have led to a global search for effective vaccines and therapeu-
tics to help boost immunity [4–6]. Health promotion models that aim to help improve
host immunity are being developed [1,7]. These often incorporate approaches such as
physical activity and exercise [1,7], nutrition [8,9], and a focus on mindfulness and mental
health [10–12]. Over recent decades, healthcare providers have increasingly embraced
a biopsychosocial model of healthcare that has incorporated approaches such as these
to healthcare promotion [13,14]. One such healthcare modality that has been shown to
influence neuroimmune chemical concentrations over the past two decades is manual
or mechanically assisted application of specific high-velocity, low amplitude (HVLA),
controlled vertebral thrusts (also known as chiropractic adjustments or spinal manip-
ulation) [15–32]. Such HVLA thrusts delivered to spinal segments appear to improve
vertebral column motor control by bombarding the central nervous system (CNS) with
mechanoreceptive input from paraspinal tissues surrounding the segment, in particular,
from the deep intervertebral paraspinal muscles [33–37]. There are known maladaptive
plastic changes in the deep paraspinal muscles following a spinal injury [38–43]. Rapid
atrophy due to neural inhibition [39,40], the development of muscle fibrosis, extensive
fatty infiltration, and changes in muscle fibre types have all been found within the deep
paraspinal muscles at various time-frames after a spinal injury [38,41–44]. The rapid and
progressive degeneration of the cervical multifidus muscles has also been found to occur
after cervical spine injuries such as whiplash, which include fatty infiltration of these deep
paraspinal muscles of the neck [45,46]. These local paraspinal muscle changes coincide
with ‘smudging’ within the primary sensorimotor cortices [47,48], and has led scientists to
conclude that disrupted or reduced proprioceptive signalling from deep paraspinal muscles
likely plays a pivotal role in driving long-term cortical reorganisation and changes in the
top-down control of the sensorimotor systems and that this plays a vital role in driving the
recurrence and chronicity of back pain [49]. Thus, the sensory (proprioceptive) information
from deep paraspinal muscles around a dysfunctional vertebral motion segment, which
for the purposes of this review will be referred to as a central segmental motor control
(CSMC) problem (also known as a vertebral subluxation or joint dysfunction), is thought to
be the driving factor in the widespread maladaptive neuroplastic changes within the CNS
responsible for altered/poor vertebral column motor control and/or the development of
chronic spinal pain syndromes.
There is clear evidence that maladaptive dysfunction of the deep paraspinal muscles
can occur [38–43,45,46]. This parspinal muscle dysfunction surrounding a CSMC problem
likely reduces the ability of the CNS to accurately perceive what is going on at that level
of the vertebral column. Over time it may be why there is a blurring of the sensorimotor
cortical areas [47,48], and this is likely to lead to poor vertebral motor control, maintaining
the CSMC problem in existence. As HVLA thrusts delivered to spinal segments have been
shown to bombard the CNS with mechanoreceptive input from the deep intervertebral
paraspinal muscles around the segment [33–37], this is the likely mechanism by which
HVLA spinal thrusts improve spinal function and CNS motor control of the spine. However,
what is less well understood is the mechanisms by which spinal HVLA thrusts can also
impact the immune system, which recent evidence suggests occurs [15–32]. Therefore, the
purpose of this narrative review is to explore the evidence that does exist for HVLA spinal
thrusts impacting immune function and to discuss the most likely mechanisms for this
impact. This review will also cover the limitations of this body of research, and highlight
what (if any) implications this has on clinical care and will discuss future research needs.
2. Materials and Methods
The following databases were searched for studies published up until April 2021:
CINAHL, MEDLINE, SPORTDiscus, Web of Science, Index to Chiropractic Literature, and
Scopus. The search strategy (Supplementary S1) included a combination of key search
terms, such as immune*, endocrine*, white blood cells, CD4, lymphocyte, chiropractic,
spinal manipulation, osteopath*, manual therapy, high-velocity low-amplitude thrust, and
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spinal adjustment. In addition, relevant search terms from recent narrative and systematic
reviews were also included to identify additional studies. The reference list of recent
systematic reviews and meta-analyses were also searched. Full-text articles published
in peer-reviewed English journals were included. Studies were excluded if they were
conference papers, commentaries, letters, books, and theses.
3. Results
Research investigating the effect of HVLA controlled vertebral thrusts on neuroim-
mune function and its potential mechanisms were extracted from the articles retrieved
from the literature search (see Supplementary S2).
3.1. Research Investigating a Link between HVLA Controlled Vertebral Thrusts and
Immune Function
Twenty-three published papers were found that explored the impact of HVLA con-
trolled vertebral thrusts on neuroimmune markers (Supplementary S2) [15–32,50–54], of
which eighteen found a significant effect (non shaded rows in Supplementary S2) [15–32].
These basic science studies will be discussed below and show that HVLA controlled
vertebral thrusts can influence the levels of immune mediators in the body, including
neuropeptides, inflammatory markers, and endocrine markers [15–32]. The potential
mechanisms for this impact will be discussed below in Section 3.2.
3.1.1. Effect of HVLA Controlled Vertebral Thrusts on Immune Mediators
A number of basic science studies have been published that have evaluated the effect
of HVLA controlled vertebral thrusts on various immune mediators, including neuropep-
tides (like neurotensin, oxytocin, and substance P), inflammatory markers (like tumour
necrosis factor (TNF) and interleukins (IL)), and endocrine markers (like cortisol and
epinephrine [15–32,50–54]. There is moderate level evidence that HVLA controlled verte-
bral thrusts impact these immune mediators [55,56]. A systematic review and meta-analysis,
that included healthy and/or symptomatic subjects, showed that HVLA controlled verte-
bral thrusts can influence neuropeptides and inflammatory biomarkers that are important
biochemicals associated with the function of the immune system [55].
There is moderate quality evidence, from one study, that suggests that HVLA con-
trolled vertebral thrusts increase neurotensin and oxytocin levels [29,55]. An RCT involving
30 healthy individuals reported that, compared to a control, both cervical and thoracic
HVLA controlled vertebral thrusts increased neurotensin and oxytocin levels immediately,
but not two hours, after the intervention [29]. Although this finding suggests that HVLA
controlled vertebral thrusts have an influence on immune function, it is not known if this
is clinically relevant, as the changes were only short term. The study was of moderate
quality and lacked blinding of participants and investigators, which is common in manual
therapy studies. In contrast, an RCT of 28 women with non-specific mechanical neck
pain found no significant difference in neurotensin, oxytocin, orexin A, and cortisol levels
between the cervical HVLA controlled vertebral thrust and sham group. However, there
was significant within group difference in neurotensin, oxytocin, and orexin A levels in the
intervention group only [32]. Neurotensin, a neuropeptide that is abundant in the CNS
and the GI tract, is an important modulator of neuroendocrine function [57–59]. It has been
shown to have an anti-inflammatory role that involves downregulating the activation of
the pro-inflammatory cytokines, such as IL-6, tumour necrosis factor alpha (TNF-α), and
IL-10 [60]. It is also involved in the regulation of the HPA axis as it is responsible for increas-
ing corticosterone and decreasing luteinising hormone, TSH and T4 production. Oxytocin
plays an essential role in the hypothalamic neuroendocrine system, which is important in
regulating immune function by regulating hormone secretion from the pituitary gland [61].
The oxytocin secreting cells can integrate neural, endocrine, metabolic, and immune infor-
mation and play a pivotal role in the development and functions of the immune system [61].
In addition, it promotes the development of thymus and bone marrow, performs immune
surveillance, strengthens immune defence, and maintains immune homeostasis [61]. It can
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also inhibit inflammation by suppressing pro-inflammatory cytokines, exert antibiotic-like
effects, promote wound healing and regeneration, and suppress stress-associated immune
disorders [61]. It is released from the posterior pituitary in response to sexual stimulation,
uterine dilatation, nursing, but also in some situations, due to stress [62].
There is low-quality evidence suggesting that HVLA controlled vertebral thrusts
increase levels of substance P [55]. As compared to a control, HVLA controlled verte-
bral thrusts increased substance P in healthy individuals immediately after the interven-
tion [15,19,28], but not after a delay [19,28]. Substance P is a neuropeptide that can modulate
immune cell proliferation rates and cytokine production [63] and alter the immune func-
tions of activated microglia and astrocytes [64]. Substance P also plays a major role in pain
perception and neurogenic inflammation [63]. However, the evidence regarding substance
P is not all positive, because it has also been shown to be involved with secondary patho-
physiology after traumatic brain injuries [65]. It has also been shown to be involved in bone
marrow fibrosis and tumor cell proliferation and to exacerbate inflammation in people
with a variety of conditions [63]. Studies on animals have even shown that substance P
induces antisocial aggressiveness and regulates emotional behaviour such as depression
and anxiety [66]. In human studies, it has been shown to be involved in negative emotions
and in addictive behaviours [66].
A recent narrative review of randomized and non-randomized controlled trials con-
cluded that the evidence for the effect of HVLA controlled vertebral thrusts on cortisol level
in healthy or symptomatic individuals is inconsistent and limited by bias from various
factors (for details refer to Colombi, 2019) [56]. Cortisol or glucocorticoids are important
modulators of the immune response because they act to suppress cytokines and inflam-
mation [67–71]. Suppression of inflammation by cortisol depends on whether the stress
is acute or chronic [72]. Following the initial pro-inflammatory sympathetic response to
acute stress, there is an increase in cortisol levels that reduces the inflammation, inhibits
non-vital organs, and mobilizes glucose to regulate the acute stress [72,73]. However,
chronic exposure to stress causing prolonged and excessive surges of cortisol depletes the
levels of cortisol that results in increased inflammatory response [74–77].
Interleukins are a group of cytokines that play a major role in immune function [71].
They are cytokines that are released by immune cells when immune cells detect pathogens
or tissue injury or in response to stress or trauma [71,78,79]. Some of them are known
to be strongly pro-inflammatory, such as IL-1 beta and TNF-α. Others are known to be
anti-inflammatory, for example IL-2, IL-4, and IL-10. However, many interleukins can be
both pro- and anti-inflammatory, particularly IL-6. There is evidence that HVLA controlled
vertebral thrusts decrease pro-inflammatory IL-1 beta and TNF-α [19], and increase anti-
inflammatory cytokines like IL-2 [20,21]. There is moderate quality evidence that spinal
manipulation influences interleukin levels [55]. An RCT that included 64 age and gender-
matched healthy asymptomatic individuals evaluated levels of IL-1 and TNF-α before,
20 min and 2 h after either a thoracic manipulation that resulted in a cavitation, a thrust
to the thoracic spine that did not cause a cavitation (sham SMT), or a control group that
received venipuncture. It was found that over the evaluation period, the sham and control
individuals showed an increase in their TNF-α and IL-1 concentrations and the group
that received manipulations with cavitation showed a decrease [19]. As TNF-α and IL-1
are both strong pro-inflammatory cytokines [78], the findings of this study indicate that
the central anti-inflammatory mechanism is influenced following an HVLA controlled
vertebral thrust.
The influence of spinal manipulation on central anti-inflammatory mechanisms is fur-
ther supported by two RCTs that measured the levels of IL-2 in healthy individuals [20,21].
In both of these studies, the IL-2 levels were measured before, 20 min and 2 h after either
a thoracic manipulation that resulted in cavitation, a thrust to the thoracic spine that did
not cause a cavitation (sham SMT), or a control group that received venipuncture [20].
Teodorczyk-Injeyan and Injeyan [20] found that in vitro synthesis of IL-2 levels increased
over the evaluation period irrespective of whether the groups received the adjustment with
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or without cavitation, but they did not increase in the control group. As the mechanical
effects of spinal manipulation may not be directly related to cavitation [80–82], the findings
of this study indicate that HVLA controlled vertebral thrusts may influence IL-2-regulated
biological responses under certain physiological conditions. Teodorczyk-Injeyan and Mc-
Gregor [21] found that over the evaluation period, IL-2 -induced immunoglobulin G and
immunoglobulin M was significantly increased in cultures from individuals who received
manipulation with cavitation. Another study found that IL-6 and C-reactive protein (CRP)
decreased after HVLA controlled vertebral thrusts with an Activator IV hand-help adjust-
ing device [24]. In contrast, there were no significant changes in concentration of IL-1β,
IL-6, IL-8, or IL-10 after 12 weeks of osteopathic treatment in people with non-specific
chronic low back pain [26]. However, concentrations of TNF-α reduced significantly in
people who received the osteopathic treatment as compared to those who received sham
treatment [26]. Similarly, a significant decrease in circulating levels of TNF-α after 12 weeks
of osteopathic manual treatment was noted in people with diabetes mellitus and comorbid
chronic low back pain [27]. No significant effect of manual treatment on IL-1b, IL-6, TNF-α,
and CRP was also noted one and 24 h after the treatment [31].
IL-2 is produced by T helper Lymphocytes, called CD4+ cells [79]. IL-2 stimulates the
cell-mediated immune response, and has an anti-inflammatory effect by reducing the pro-
inflammatory effects of IL-6 [83]. IL-2 controls the growth and differentiation of both T and
B Lymphocytes [79]. It also promotes self-tolerance and inhibits the growth of some human
tumor cells [79]. IL-2 is currently being used to treat auto-immune disorders and various
cancers [84–86]. However, there are still unanswered questions about whether this increase
has a clinically relevant impact on immunity, whether a similar increase can be seen in
people with various pathological conditions, how long this effect lasts, and whether it has
a positive impact in patients with autoimmune conditions, or cancer patients, or whether it
has an anti-inflammatory effect. More research is needed to answer these questions.
There is some evidence that the impact of HVLA controlled vertebral thrusts on
immune mediators may be useful in various pathological conditions. Six sessions of
HVLA controlled vertebral thrusts to the affected areas was reported to reduce the elevated
inflammatory mediators found in people with low back pain [22]. However, levels did
not reduce to the level of the asymptomatic control individuals. People with non-specific,
acute and chronic low back pain have elevated levels of some inflammatory mediators
compared to control subjects [22,56]. This may be due to the inflammation occurring at
the level of joint dysfunction or CSMC problem as micro-trauma may be occurring to the
tissues at the site, since the CNS is less accurately aware of what is happening due to the
neurological inhibition of the deep small paraspinal muscles. The motor control of the
spine at this area is less likely to be appropriate and hence micro-trauma may be occurring
repetitively. It has also been suggested that patients with chronic pain, such as chronic low
back pain or fibromyalgia, have dysfunctional cortisol levels, which may be the cause of the
inflammation and are linked to pain hypersensitivity [56,87]. This makes sense, as cortisol
is an immunomodulator and responsible for ensuring that inflammation is not carried on
unchecked, which is what is occurring in chronic pain conditions [50,87]. Research suggests
that HVLA controlled vertebral thrusts influence cortisol levels, as discussed above, this
may provide some insight into pain reduction in these groups.
A study by Selano and Hightower [17] monitored CD4 cell counts in 10 HIV positive
individuals over a 6-month period. Five patients received upper cervical only adjustments
(treatment group) and five were in a control group. In the adjustment group, 48% higher
CD4 counts were noted at the end of the 6-month period, while the control group had an
8% decrease in their levels [17]. A note of caution is due here since the results were not
statistically significant. In addition, as the results were poorly reported, it may be heavily
swayed by a single person or other limitations of the study.
Other studies have investigated the impact of HVLA controlled vertebral thrusts on
people with other immunologically mediated conditions like asthma [88–91]. Generally,
the results of these studies have not been strong enough to make any conclusions about the
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effectiveness of HVLA controlled vertebral thrusts to help people with these conditions.
Systematic reviews tend to report that either there is not enough evidence to say HVLA
controlled vertebral thrusts help children with asthma [90], or that the results are nega-
tive [89,92]. Larger, good quality studies are needed to establish whether there is a link
between HVLA controlled vertebral thrusts and the immune response in immunologically
mediated conditions.
3.1.2. Effects of HVLA Controlled Vertebral Thrust on the Autonomic Nervous System
It is now accepted that the ANS and HPA axis influence the immune response and
stress response [70,93–112]. However, these systems are impossible to separate, as they are
highly coordinated and physically interconnected [113]. The evidence for an effect of HVLA
controlled vertebral thrusts on ANS function related to the immune response is limited [55].
A single, low-quality study found no effect of HVLA controlled vertebral thrusts on
epinephrine and norepinephrine levels [54]. Another study found that application of
HVLA controlled vertebral thrusts did not influence the HPA axis in symptomatic and
asymptomatic males [50]. Most of the literature in this area has focussed on other aspects of
ANS function that may be impacted by HVLA controlled vertebral thrusts [114,115]. Some
studies have shown that HVLA controlled vertebral thrusts may positively impact various
aspects of ANS function, such as heart rate variability, cardiovascular function, respiratory
function, gastrointestinal function, and genitourinary function [114,115]. However, most
of these studies are basic science studies [114,115] and more clinically relevant trials are
needed to evaluate how HVLA controlled vertebral thrusts impact ANS function and
whether this is clinically relevant with respect to immune function.
3.2. Potential Mechanisms That Link HVLA Controlled Vertebral Thrusts with Immune Function
In the past, it was thought that the CNS and the immune system functioned relatively
independently [116]. However, more recently, the strong, interconnected relationship
between the CNS and the immune system has received significant attention from the
research community [117]. As HVLA controlled vertebral thrusts have been shown to
impact the CNS, and the CNS is known to strongly influence immune function, this
provides a plausible biological mechanism to explain how HVLA controlled vertebral
thrusts could impact immunity. This section will discuss these potential functional links.
3.2.1. The Link between HVLA Controlled Vertebral Thrust and the Central
Nervous System
A growing body of research conducted by chiropractors has shown that chiroprac-
tic HVLA controlled vertebral thrusts (also called chiropractic adjustments) affect the
CNS [118–135]. It has been hypothesized that adjusting CSMC problems in the spine,
alters the afferent input from the small paraspinal muscles around the spine and skull
to the brain [123,136]. This affects how the CNS processes and integrates all subsequent
sensory input, such that the brain senses more accurately what is happening in and around
the body, so there is improved brain–body awareness, adaptability, and coordination and
therefore, better function [123,131].
One of the keys to this proposed model is the proprioceptive role played by the small
intervertebral muscles closest to the spine and skull. It is now well established that these
small paraspinal muscles are very important sensors used by the brain to help control
posture and spinal movement patterns [137,138]. It has been hypothesized that CSMC
problems alter the afferent input from the small paraspinal muscles to the CNS, which
impacts the brain’s awareness of what is happening in the body [123,136,139–141]. This, in
turn, may affect subsequent afferent feedback from associated structures in the spine and
limbs, which has a flow-on effect on how the brain processes and interprets other internal
and external sensory information. Ultimately, this can lead to altered sensorimotor and
multimodal integration and a lack of awareness in the CNS of the state of the body’s inter-
nal and external environment [132,136]. Over time, maladaptive changes in neural function
affect the way we respond to our internal and external environment, potentially leading to
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a lack of adaptability and resilience and the development of symptoms, diseases, and disor-
ders [123,136,139–141]. If, by adjusting CSMC problems, the associated rapid stretch of the
deep paraspinal muscles enhances proprioceptive afferent input from these muscles, this is
thought to improve brain–body awareness, adaptability, and resilience [123,127,140,141].
There is a growing body of research that supports this neuroplasticity model of
spinal dysfunction and HVLA controlled vertebral thrusts. Some studies have shown
neural plastic changes, such as altered sensorimotor integration and motor control, af-
ter HVLA controlled vertebral thrusts [123–125,128,131,135]. Other studies have shown
improvements after HVLA controlled vertebral thrusts in muscle strength and motor
neuron excitability in normal healthy adults and elite athletes, as well as in adults with
brain injuries, in particular stroke survivors [120,133,135]. Studies have also shown that
HVLA controlled vertebral thusts affect cerebellar function, particularly the communica-
tion between the cerebellum and the motor cortex, which has a key role in sensorimotor
integration [119,121,142]. Thus, it is quite clear that HVLA controlled vertebral thrusts can
impact vital parts of the brain involved in creating internal and external schemas or maps
of the internal and external environment.
More importantly, there is evidence suggesting that chiropractic HVLA controlled ver-
tebral thrusts have a significant effect on the prefrontal cortex [134]. Using brain electrical
source localization analysis, it has been identified that adjusting CSMC problems in the
spine impacts the prefrontal cortex [134]. The prefrontal cortex is a high level processing
centre of the CNS and is described as the executive controller of the CNS [134,143]. It is
also a key multimodal association cortex and has functions in motor control and senso-
rimotor integration through directing and sensing perception of self, attention, memory
sequence processing, and motivation [143]. The prefrontal cortex is also known to be vital
for proper immune system function [94,144–154]. The prefrontal cortex regulates the ANS,
directly activates the vagal cholinergic anti-inflammatory system, and impacts the hor-
monal system, in particular the hypothalamus–pituitary–adrenal (HPA) axis [94,144–154].
In addition, these mechanisms impact pain processing [149,155–157] and all aspects of
emotional control and mental health [158–163]. Therefore, since HVLA controlled verte-
bral thrusts influence the CNS, in particular the prefrontal cortex, which in turn has an
impact on the ANS, HPA axis, and immune system, this provides a biologically plausible
mechanism for how HVLA controlled vertebral thrusts may impact immune function.
3.2.2. The Link between the Central Nervous System and the Immune System
The CNS and the immune system are the two primary systems in humans and animals
that are responsible for detecting and responding rapidly to our internal and external
environment, and they are closely linked, both physically and physiologically [164,165].
This bidirectional communication between the two systems helps to maintain homeostasis,
where the immune system acts as a sensory system providing information to the CNS and
the CNS responds via the neuroendocrine system, autonomic nervous system, and the
meningeal lymphatic system [116,164–169]. Mounting evidence suggests small clusters
of neurons, glial cells, and immune cells, called neuro–immune cell units (NICUs) are
found throughout the body and functionally interact with each other to sense what is
going on in and around us, to protect us from invading pathogens and injuries [165]. The
immune cells are equipped to respond to neurotransmitters and neuropeptides secreted by
neuronal signals and neurons and glial cells can sense and respond to immune-derived
cytokines [165].
There is emerging evidence showing that the CNS and the immune system are in-
terconnected and function in close association with each other [170–172]. Activation of
the immune system has been shown to influence brain function, for instance, immune
cells and cytokines released in response to peripheral inflammation affect brain processes
such as sleep [173,174], appetite and satiety [175,176], learning and memory [177], be-
havior [178,179], and neurocognitive function [180,181]. The brain is also capable of
impacting immunological reactions. Even one’s mental and emotional state can alter the
Medicina 2021, 57, 536 8 of 26
response to disease or a therapeutic intervention [182,183]. For instance, anticipating nega-
tive consequences can result in negative outcomes, referred to as nocebo response [182],
whereas expecting positive results from an intervention can lead to improvement in dis-
ease state as observed in the placebo effect [183]. Moreover, the brain keeps a check
on immune activity following a neurological lesion such as stroke, in order to protect
itself from an excessive immune response [170,184]. However, this attenuation of im-
mune response makes post-stroke individuals more prone to chest infections [185]. No-
tably, the side of stroke lesion impacts the immune response, indicating that the left or
right hemispheres of the brain may have differential effects on peripheral immune re-
sponses [186–190]. This may be due to their distinct connections with the sympathetic
nervous system (SNS) and the parasympathetic nervous system (PNS) [191–194]. Multiple
disciplines, including neuroscience, psychology, immunology, and endocrinology, have
explored theories of possible neuroimmune mechanisms in diseases, such as neurocogni-
tive disorders like Alzheimer’s disease; respiratory diseases, such as asthma; autoimmune
disorders; mood disorders, such as depression; and in general infection and inflammation
processes [67–70,93,116,117,164,166,180,181,195–201]. Through this research, it is now well
established that there is indeed a strong neuro-immune link [116,165,166].
Neuro-immune communication also occurs within the brain tissue through parenchy-
mal resident cells called microglia and immune cells present in the meninges and choroid
plexus [170]. In addition, neuro-immune responses also take place at sites where blood
vessels directly or indirectly interact with the brain, such as at the circumventricular or-
gans (CVOs) or blood–brain barrier (BBB). As all the above structures are innervated,
neuronal activity can influence the immune response by altering the permeability of the
BBB, modulating the activity of the epithelial cells in the CVOs, or affecting the secretion
of chemotactic substances in the meninges and choroid plexus. For instance, depressive
disorders, sleep deprivation, or severe stress reduce BBB permeability [202] and alter B-cell
homing [203] or leukocyte trafficking through the choroid plexus [204]. Furthermore, the
microglia and other brain cells are also affected by neuronal activity, as the activation
of their neurotransmitter receptors affects their function [205–209], indicating complex
neuroimmune interactions.
The basis of the neuroimmune dialogue and the reasons for it have been discussed
in a recent review [170]. Schiller and Ben-Shaanan [170] argue that the unique features
and functions of the brain can provide three additional benefits to the immune system.
First, the brain’s ability to integrate and synchronize physiological processes, such as body
temperature, blood flow, metabolism, digestion, cardiovascular, and renal function, may
be useful to prepare the individual for an upcoming threat or challenge. One example of
this is the hypothalamus-mediated loss of appetite, which facilitates fasting behavior to
survive a septic shock, as increasing caloric intake is not always useful to support immune
activity [210,211]. Immune activation is metabolically costly [212–214]; therefore, synchro-
nizing immunity with physiological functions may be useful for an effective immune
response. The suprachiasmatic nucleus of the hypothalamus, known as the inner clock,
regulates the circadian rhythm, which has been shown to synchronize the immune sys-
tem [215–217]. Another critical structure involved in immune synchronization is the insula.
Insula activity is important for detecting proprioceptive inputs and producing corrective
actions, that may include immune activity, to promote homeostasis [218,219]. Second,
the brain’s ability to make predictions and anticipate threats may be useful to detect and
assess danger before it physically harms the individual. The insular cortex, amygdala, and
ventromedial nucleus of the hypothalamus are regulators of immune conditioning [220],
a response similar to Pavlonian conditioning [221]. Activation of brain areas involved
with anticipation of behaviour may lead to immune priming. Priming of antibacterial
immunity has been reported with the activation of the ventral tegmental area, which is
involved in positive expectations [222–225]. Pain may be another factor which is important
for the prediction of upcoming threats. Pain-sensing neurons and brain areas responsible
for modulation of pain, particularly the periaqueductal grey, have been shown to affect
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immunity [169,226–230]. The primary and secondary somatosensory cortex, the anterior
cingulate cortex, the insula, the prefrontal cortex, the thalamus, and the cerebellum are the
brain areas most activated by painful stimuli [231]. Lastly, the brain’s capacity to respond
quickly, may facilitate rapid immune responses during stressful events, in order to prepare
for impending danger [117,232,233].
There are two main pathways involved in CNS–immune system communication:
(1) the neuroendocrine system and (2) the ANS, including both (a) the SNS and (b) the
PNS [67,68,70,94,116,117,164,234]. Other pathways that contribute towards the neuro-
immune communication are the sensory system and the meningeal lymphatic system [170].
3.2.3. The Neuroendocrine System
The main brain structure that controls the endocrine system is the hypothalamus.
It responds to peripheral inflammation by releasing hormones into circulation at the
CVO [235,236]. Any change in hypothalamic activity can impact the immune response. For
example, injury to the lateral hypothalamus disrupts the number of immune cells in circu-
lation [237,238] and impacts natural killer cell cytotoxicity in the bloodstream [239]. The hy-
pothalamus regulates the endocrine system through the hypothalamic–neurohypophyseal
system and the hypothalamic–hypophyseal portal system, which are necessary for effective
immune activity [170]. The hypothalamic–neurohypophyseal system, comprising of the
hypothalamus and the posterior pituitary gland, directly releases oxytocin [240,241], and
arginine–vasopressin (AVP) [242] from the neurosecretory cells into the bloodstream for the
regulation of immune activity. The hypothalamic–hypophyseal portal system constitutes
the release of hypothalamic hormones, which stimulates the secretion of anterior pituitary
hormones into the bloodstream so that it can ultimately cause the release of relevant hor-
mones from the target organ for the regulation of various physiological processes [170].
For instance, the release of cortisol from the adrenal glands regulates the stress response
(HPA axis), the release of thyroid hormone from thyroid glands regulates metabolism
(hypothalamic–pituitary–thyroid axis), the release of sex hormones from gonads regulates
reproduction (hypothalamic–pituitary–gonadal axis), the release of prolactin affects the
production of milk in females (hypothalamic–pituitary–prolactin axis) and the release
of growth hormones and insulin-like growth factor 1 (IGF-1) regulates growth or blood
glucose levels (hypothalamic–pituitary–somatotropic axis). All these hormones impact
our immune responses; for instance, estrogen enhances immunity, which is why females
have been shown to produce a higher number of antibodies and are less prone to viral
infections [243,244]. However, this also makes them more susceptible to autoimmune
diseases [245,246]. Another example is thyroid hormone, which activates the prolifer-
ation of lymphocytes [247]. Absence (thyroidectomy) or attenuation of this hormone
(hypothyroidism) suppresses the immune response [248] or increases the susceptibility to
infections [249,250], respectively.
3.2.4. HPA Axis
The hypothalamus, pituitary, and adrenal gland form the HPA axis. The HPA axis can
modulate the immune system by responding to immune mediators, such as cytokines and
eicosanoids that have been released from the immune cells due to some infectious pathogen,
injury, trauma, stress, or any kind of immune challenge [67,68,70,71,93,95,201]. NICU’s
detect immune challenges throughout the body and promote the release of cytokines,
such as IL-1, IL-6, and TNF-α, and eicosanoids in order to activate a local inflammatory
response [67,71,93,201]. Once these immune mediators are released, this is communi-
cated to the brain via blood and vagal sensory afferent fibres [95]. Afferent fibres of the
vagus nerve project to the brainstem and then through an ascending link to the hypotha-
lamus [67,68,71,93,95,201]. These immune mediators can then activate the HPA axis. In
response, the hypothalamus releases corticotrophin releasing hormone (CRH) which trig-
gers the release of adreno-corticotrophic hormone (ACTH) by the pituitary gland, which
in turn stimulates the release of glucocorticoids by the adrenal gland [67,68,70,71,93,201].
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Glucocorticoid steroids act in an immunomodulatory manner by regulating and suppress-
ing the immune response through the modulation of cytokines and other inflammatory
mediators, in order to limit overactive or detrimental responses [67,68,71,93,95,201]. In a
healthy system, this is balanced by other pituitary hormones, such as prolactin, growth
hormone and also thyroid hormones, so that chronic immunosuppression does not occur
and homeostasis is maintained [196].
3.2.5. The ANS
The other primary mechanism by which the CNS and immune system interacts, is
through the ANS, via both the SNS and the PNS divisions [70,93–97]. The dorsal motor
vagal nucleus [251] or the rostral ventrolateral medulla [252], locus coeruleus (LC) [253],
A5 [254,255], and the rostral raphe pallidus [256,257] are the key areas involved in the
regulation of the ANS pathways, which send signals to the periphery and impact im-
mune responses.
3.2.6. The SNS
The SNS has a dual role in the immune response, as it has both pro-inflammatory and
anti-inflammatory actions [95]. The SNS innervates lymphoid organs, such as the spleen,
bone marrow, and tonsils, and communicates with immune cells in these organs via the
neurotransmitter norepinephrine, also known as noradrenaline [70,93,95–97]. The SNS
can modulate blood flow and immune cell distribution [165]. Through the SNS’s release
of norepinephrine, it acts to modulate the response of CD4 T-cells and B-cells during an
immune response against an antigen [166].
The SNS also interacts with the adrenal gland through adrenoreceptors, here they act
to stimulate glucocorticoid (cortisol and cortisone) and catecholamine (epinephrine and
norepinephrine or adrenaline and noradrenaline) release from the adrenal glands, which
then modulate the level of cytokines. The SNS can, therefore, also have a direct hormonal
effect by activating the adrenal glands.
3.2.7. The PNS
The PNS also has a known neuro-immune effect via the vagus nerve [94,95]. This
is known as the cholinergic anti-inflammatory system, because the vagus nerve releases
acetylcholine (ACH). The ACH release, due to parasympathetic activity, inhibits pro-
inflammatory cytokines such as IL-6 [83,94]. The activity of the PNS drives this cholinergic
anti-inflammatory system by the release of ACH in the reticuloendothelial system, which
includes the liver, heart, spleen, lungs, blood, general connective tissue, gastrointestinal
tract, bone marrow, and lymph nodes. The ACH interacts with receptors on macrophages
to inhibit the release of pro-inflammatory cytokines. This is how the PNS can modulate the
function of the immune system, but it should be noted that the PNS also plays an important
sensory role in the body/brain connection, as it senses the presence of pro-inflammatory
cytokines in the body and conveys these signals to the brain.
3.2.8. The Sensory System and the Meningeal Lymphatic System
The sensory system, via sensory neurons, detects potential threats in peripheral tissue
and releases neuropeptides that influence the immune cells in the periphery [258,259]. They
also send relevant information from the periphery to the brain [170]. An additional way
by which the brain influences the immune function is through the meningeal lymphatic
system. The brain releases brain-specific antigens and immune cells into the lymphatic
vessels surrounding the brain, which transports it to the peripheral lymph nodes to affect
the peripheral and central immune response [170].
3.2.9. Stress Negatively Impacts Immune Function and Vertebral Motor Control
It is now accepted that negative emotional stress has a major impact on the CNS
and immune function [69,144,151,195,260–262]. Stressful mental and emotional states
Medicina 2021, 57, 536 11 of 26
suppress peripheral immunological activity and cause increased susceptibility to infec-
tion, as noted in depression [263–266]. In addition to infections, injuries, pathogens or
inflammation, emotional stress can also activate our ANS, in particular the SNS and it
can activate the HPA stress axis in a way that has negative long term implications for
our health [69,151,195,196,260,267,268]. This increases levels of glucocorticoids (like cor-
tisol) and catecholamines (like epinephrine and norepinephrine) that can alter cytokine
levels (such as increasing IL-6 pro-inflammatory cytokines), which then alters the levels
of inflammation throughout the body [67–70,96,97,116,117,164,195,268]. Over time, this
can weaken the immune system, and put the individual at risk of having more frequent,
prolonged, or excessive immune reactions [67–70,96,97,116,117,164,195,268]. We also know
negative emotional stress inhibits the prefrontal cortex from operating properly [144,260],
which also has detrimental effects on the ability of the PNS to activate the cholinergic
anti-inflammatory pathway [94,144,145]. Dysfunction within the prefrontal cortex is also
likely to impact on its normal inhibition of the HPA axis [154]. Therefore, with stress
increasing inflammation via the HPA axis and the SNS, and supressing prefrontal cortex
function, which reduces its suppression of the HPA axis and inhibits its activation of the
PSN’s cholinergic anti-inflammatory system (via the vagal nerve), it is not surprising that
negative emotional stress, over long periods of time, may lead to higher inflammatory
levels in the body [269–271].
Excessive levels of inflammation in adults has been linked to a host of mental and
physical diseases and disorders, such as autoimmune diseases, diabetes, coronary artery
disease, cancer, Alzheimer’s disease, obesity, depression, anxiety, PTSD, pulmonary disease,
various neurological diseases, chronic pain and arthritis, ulcerative colitis, and Crohn’s
disease [95,98–112]. Chronic inflammation has even been suggested to be one of the key
biological mechanisms that leads to a decline in physical function, potentially then, as we
age, resulting in frailty, disability, and ultimately, death [98,272]. Acute and chronic stress
have a distinct impact on the immune response. Studies on animals and humans have
shown that acute stress enhances the immune response [232,273], whereas chronic stress
suppresses the immune system [274–276]. For example, acute stress experienced during
parachute jumping or solving a difficult arithmetic exam increases the activity and number
of natural killer cells and CD8+ T cells [233,277]. Prolonged exposure to a stressful life
situation has been shown to attenuate immune gene cell expression [169,278–280]. Research
studies have established that chronic stress and psychological stress slow wound healing,
can increase the severity and duration of infectious diseases, such as respiratory infections,
and it can reactivate latent viruses in the body, and there is even evidence that suggests that
stress can reduce the response to some vaccines [69,93,195,196]. Other studies have shown
that people who experience higher levels of psychological stress are more susceptible to
getting the common cold, immune-related disorders, and respiratory infections [268,281].
Chronic stress causes accumulation of pro-inflammatory leukocytes due to hematopoietic
stem cell proliferation in the bone marrow [282].
Interestingly, there is growing evidence that shows that stress may also impact verte-
bral motor control [283–285]. Executing tasks under the influence of psychological stress
has been shown to alter muscle activation patterns, as noted in trunk muscles during a
lifting task [286] and shoulder muscles during a keyboard task [287]. Stress may also have
differential effects on muscle activation, depending on the type of muscle. Exposure to
acute psychological stress increases the activation of bigger muscle groups while inhibiting
the deep small muscles [288]. Increased activation in the upper trapezius muscles has been
noted during acute psychological stress [289]. Stress-induced increase in SNS activation or
disinhibition of the reticular formation, which under non-stressful situations is responsible
for inhibiting the trapezius muscle during ongoing movement, has been suggested to cause
the increased trapezius activation [290]. On the other hand, acute psychological stress has
also been shown to inhibit small paraspinal muscles close to the spine and the skull [288].
Both these responses can be explained by the stress-induced effects of the SNS on muscle
spindle activity, such that increased sympathetic outflow depresses muscle spindle activa-
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tion and changes the feedback control of muscle length and movement [291]. An example
of this is seen when enhanced sympathetic outflow attenuates precise and fine movement
control to ensure fast and gross movements during a life-threatening situation. However, if
the increase in sympathetic outflow occurs in situations that require accurate and continu-
ous proprioceptive feedback, it may result in inaccurate performance outputs that result
in maladaptation. Such stress-induced changes in muscle afferent signaling that lead to
maladaptations may be responsible for chronic muscle pain and dysfunction [291,292].
Another likely reason for stress-induced change in vertebral motor control may be
related to pain or pain-related fear of movement. In people with chronic pain, alterations in
paraspinal muscle control have been found to be associated with self-reported measures of
anxiety and distress, instead of just the intensity of pain [293–295]. This may indicate that
the stress associated with pain may change the activation of trunk muscles. A delay in the
response of deep spinal muscles during fast arm movements has been noted when people
with experimentally induced pain performed tasks with negative feedback of performance
and negative cues [283]. There is also evidence of differential trunk muscle activity in
fearful and non-fearful back pain patients, such that people who are more fearful have
less relaxation [296] and lower endurance of paraspinal muscles at the end range of trunk
flexion [297]. Another study found that fear of movement resulted in decreased upper
trapezius muscle activity in people with post-traumatic neck pain and that the effect was
stronger when the intensity of pain was higher [298]. A positive link between fear of
movement and trunk stiffness was reported in people with low back pain, with greater fear
of movement and fear-avoidance beliefs being associated with greater trunk stiffness during
forward perturbation [299].Therefore, stress related to pain or negative emotions alters the
muscle activation patterns of our body and impacts vertebral motor control. This occurs by
stress-induced effects of SNS on muscle spindle activity that changes the muscle activation
and cause maladaptation. If the CNS is not able to perceive accurately what is happening
at that spinal level, with the small deep paraspinal muscles neurologically inhibited, then
it makes logical sense that it cannot control this part of the spine appropriately, hence
a central segmental motor control problem may arise that over time leads to repeated
microtrauma at that area of the spine, which chiropractors and other manual therapists
can palpate. Therefore, stress may be a major cause of what chiropractors refers to as
vertebral subluxations, i.e., “a self-perpetuating, central segmental motor control problem
that involves a joint, such as a vertebral motion segment, that is not moving appropriately,
resulting in ongoing maladaptive neural plastic changes that interfere with the central
nervous system’s ability to self-regulate, self-organize, adapt, repair and heal” [300].
3.2.10. Summary of the Neuroimmune Link
Stress weakens our immune response and makes us more susceptible to infections
such as respiratory diseases [95,98–112]. Attenuation of the immune response occurs due
to increased inflammation induced by stress either directly through the activation of SNS
and HPA axis or indirectly via suppression of the prefrontal cortex to reduce the inhibition
of HPA axis and supress anti-inflammatory PNS activity. Furthermore, under normal
circumstances, the neuro-immune dialogue is integral for the maintenance of homeostasis
in the body. There is substantial evidence that shows the nervous system, the hormonal
system and the immune system communicate with one another and are intimately linked
in their functions [70,93–97]. The NICUs present within the brain and throughout the body
forms the basis of this neuro-immune interaction such that the neurons and glial cells
sense and respond to immune-derived cytokines, while the immune cells are equipped to
respond to neurotransmitters and neuropeptides secreted by neuronal signals [165]. This
interaction allows the immune system to maximise its functioning by capitalizing on the
brains ability to synchronize physiological processes, anticipate threats and act swiftly.
Various brain structures, including the suprachiasmatic nucleus of the hypothalamus, the
amygdala, the ventromedial nucleus of the hypothalamus, the periaqueductal grey, and
the insular cortex impact the immune system [170,215,216,220,229]. More importantly, the
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prefrontal cortex is critically involved in regulating the autonomic nervous system, the
endocrine system and therefore the immune system [94,144–154].
4. Implications, limitations, and Recommendations for Future Research
It is clearly now well-established that the CNS and immune system are very closely
linked and rely on each other to accurately detect an immune challenge, and together they
launch and regulate an appropriate immune response [70,93–97]. The NICUs around the
body sense invading pathogens, stress, injury, or any other immune challenge. This is
signaled to the brain in two ways: directly via vagus afferent nerve fibers, or indirectly
via the bloodstream. The afferent nerve fibers, particularly the sensory neurons, not only
carry the information from the periphery to the brain but also release neuropeptides in the
periphery to impact the local immune response [258,259]. Immune-related signals carrying
information about the brain’s condition is delivered from the brain to the peripheral lymph
nodes via the meningeal lymphatic system. The brain mainly modulates the immune
system via two main pathways, the HPA axis and ANS. The HPA axis and both divisions
of the ANS are activated by immunogenic stimuli and both contribute to the modulation
of inflammation. They do this by releasing glucocorticoids (cortisol and cortisone) and
catecholamines (epinephrine and norepinephrine), that regulate inflammatory mediators
such as cytokines. The prefrontal cortex is involved in regulating the autonomic nervous
system, the endocrine system and the immune system [154]. Additional communication
between the CNS and the immune system occurs within the brain parenchyma and sites
such as the BBB or CVO. The CNS and immune system function is affected by stress. Stress
affects our immune response and makes us more prone to infections [95,98–112]. Stress,
pain, or pain-related stressors also impact our muscle activation patterns during movement,
which may lead to maladaptive changes over time.
A growing body of research suggests HVLA thrusts directed at CSMC problems
affect the CNS [118–124,126–135], and in particular affect processing in the prefrontal
cortex [134]. This provides a biologically plausible mechanism for how HVLA controlled
vertebral thrusts could have an impact on immune function [55]. Figure 1 depicts many
of the potential links between HVLA controlled vertebral thrusts and immune function
previously discussed.
This review of the literature shows that there is basic science evidence that HVLA
controlled vertebral thrusts can modulate immune mediators, such as neurotensin, oxytocin,
substance-P, and interleukin levels in healthy asymptomatic individuals in the short-
term [55]. In addition, they may influence cortisol levels in symptomatic and asymptomatic
individuals [29]. However, most of the studies included in this review evaluated the
immune mediators immediately pre- and post-HVLA controlled vertebral thrusts, or a
few hours later on the same day [15,20,21,28,29]. Therefore, it is not known for how long
these changes in levels of immune mediators last. The studies did not evaluate what these
changes mean in patient populations in the long-term or whether the changes are clinically
relevant. Therefore, although the current basic science research on this topic is positive,
one needs to be cautious about making any claims on the use of HVLA controlled vertebral
thrusts to enhance a patient’s immunity, because no high quality clinical trials have been
performed to assess this important question.
In the studies that were reviewed, there were also some important differences in the
way that the markers were collected. For example, some markers were collected via blood
samples and some via saliva. The collection of blood samples, which requires needle
puncture, could induce a stress response itself and affect the results. Such limitations must
be considered when discussing these results. It is also important to know that results from
some studies are conflicting. Therefore, the whole picture is far from clear at this stage.
Whether changes in the immune mediators observed after HVLA controlled vertebral
thrusts enhances immune function, reduces inflammation, promotes recovery, or sup-
presses stress-associated immune disorders in symptomatic individuals is not yet known.
Chiropractors and other manual therapists should be aware that clinically relevant research
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has not yet been done that shows that HVLA controlled vertebral thrusts enhance immune
function [301]. This is important for all manual therapists to know when promoting the
potential benefits of HVLA controlled vertebral thrusts or when sharing information related
to HVLA controlled vertebral thrusts and immunity or the COVID-19 pandemic. Further
long term studies, with appropriate sample sizes, that investigate immune responses or
clinically relevant measures of immune function, are required to obtain more insights
about the biological effects of HVLA controlled vertebral thrusts on immune function [56].
Studies such as these are imperative in order to gain a better understanding about the
potential impact of HVLA controlled vertebral thrusts on immune function.
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HPA: Hypothalamus–pituitary–adrenal axis, ANS: Autonomic nervous system, SNS: Sympathetic nervous system, PNS: 
Parasympathetic nervous system, CRH: Corticotrophin releasing hormone, ACTH: Adreno–corticotropic hormone, IL: 
Interleukin. 
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5. Conclusions
There is substantial evidence suggesting that the nervous system, the hormonal sys-
tem and the immune system communicate with one another and are intimately linked
in their functions [70,93–97]. This communication is essential for the body’s ability to
protect itself and involves a variety of immune mediators, including cytokines, neuro-
transmitters, hormones, and humoral factors [67,68,70,94,116,117,164,234]. Furthermore,
the prefrontal cortex is critically involved in regulating the autonomic nervous system,
the HPA axis, and the immune system [94,144–154]. Neuro-immune communication is
affected by emotional or pain-related stress [69,144,151,195,260–262]. Stress activates the
SNS and HPA axis to increase inflammation in the body. Stress also suppresses the pre-
frontal cortex, which in turn reduces its inhibitory control on the HPA axis and inhibits the
anti-inflammatory PNS activity. This stress-induced inflammation weakens the immune
response [95,98–112]. The stress-induced SNS activity also alters the muscle activation
patterns to impair vertebral motor control [283–285], thus can cause the establishment of
CSMC problems. HVLA controlled vertebral thrusts have been shown to affect vertebral
motor control [123–125,128,131,135], the prefrontal cortex [134], and the levels of immune
mediators in the body that are important for a healthy immune response [15–32]. Although
there is a biologically plausible mechanism for how HVLA controlled vertebral thrusts may
influence the immune system, it is not yet known whether these changes have a clinically
relevant impact on immunity [55]. More large-scale clinical trials are needed to understand
whether HVLA controlled vertebral thrusts can improve immunity or recovery from illness.
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